A well-defined contamination control program is essential to maintain quality through aseptic manufacture of parenteral drug products.
Joe McCall
Advertisement
Joe McCall, previously with STERIS, is the Associate Director of QA Technical Service at ADMA Biologics.
Articles by Joe McCall
Advertisement
Latest Updated Articles
How a Contamination Control Program Impacts Product SterilityPublished: May 2nd 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
2
Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One
3
Takeda’s Sriman Banerjee Discusses Smart Packaging at CPHI Frankfurt 2025
4
Standardizing Operations to Meet Global Sustainability and Resilience Goals
5
